MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.06
+0.50
+4.33%
After Hours: 12.06 0 0.00% 16:00 09/25 EDT
OPEN
11.52
PREV CLOSE
11.56
HIGH
12.21
LOW
11.45
VOLUME
732.80K
TURNOVER
--
52 WEEK HIGH
27.15
52 WEEK LOW
7.52
MARKET CAP
914.49M
P/E (TTM)
-3.3804
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Gossamer Bio Announces Participation in Upcoming Investor Conferences
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation in two upcoming investor conferences. Sheila Gujrathi
Business Wire · 09/10 12:07
Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001
Business Wire · 09/07 16:00
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients
Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today dosing of the first patient with razuprotafib in the I-SPY COVID Trial (NCT04488081), a phase 2 platform trial aimed at improving treatment of acute respiratory distress
PR Newswire · 09/01 21:30
CRM, HPE, LRN and GOSS among after-hours movers
Gainers: [[CRM]] +12.9%. [[URBN]] +12.3%. [[HPE]] +7%. [[INTU]] +5.6%. [[BWAY]] +5.1%.Losers: [[PSTG]] -7.7%. [[LRN]] -5.9%. [[JWN]] -5.5%. [[GOSS]] -4.9%. [[ZYME]] -4.5%.
Seekingalpha · 08/25 21:46
Gossamer Bio Q2 EPS $(1.00) Down From $(0.74) YoY
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(1.00) per share. This is a 35.14 percent decrease over losses of $(0.74) per share from the same period last year.
Benzinga · 08/11 20:03
Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present fou
Business Wire · 08/05 12:31
Gossamer Bio's Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Gossamer Bio.
Zacks · 07/22 12:12
Is Gossamer Bio, Inc. (GOSS) A Good Stock To Buy?
Insider Monkey · 07/03 23:27
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GOSS. Analyze the recent business situations of Gossamer Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GOSS stock price target is 28.63 with a high estimate of 36.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 147
Institutional Holdings: 58.67M
% Owned: 77.37%
Shares Outstanding: 75.83M
TypeInstitutionsShares
Increased
59
12.35M
New
42
2.12M
Decreased
12
1.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.23%
Pharmaceuticals & Medical Research
+1.35%
Key Executives
Non-Executive Chairman
Faheem Hasnain
Non-Executive Chairman
faheem Hasnain
President/Chief Executive Officer/Co-Founder/Director
Sheila Gujrathi
Chief Financial Officer
Bryan Giraudo
Executive Vice President/General Counsel
Christian Waage
Director
Russell J. Cox
Other
Jakob Dupont
Other
Luisa Salter-Cid
Independent Director
Joshua Bilenker
Independent Director
Kristina Burow
Independent Director
Russell Cox
Independent Director
Thomas Daniel
Independent Director
Renee Gala
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GOSS
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension. GB004 is being developed for Inflammatory Bowel Disease (IBD). GB1275 is a CD11b agonist.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Gossamer Bio Inc stock information, including NASDAQ:GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.